Maher Albitar

Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.

Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels.

Emerging information on the use of rituximab in chronic lymphocytic leukemia.

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.

Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients.

Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease.

Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in BAL.

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Myelodysplastic syndrome is not merely "preleukemia".

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not.

Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.

Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.

Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer.

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.

Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.

Differences in CD33 intensity between various myeloid neoplasms.

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

Chronic lymphocytic leukemia with t(14;18) and trisomy 12.

Association of cancer-related symptoms with physiological parameters.

The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.

Presence of restricted killer immunoglobulin-like receptor repertoire and monoclonal T-cell receptor gamma rearrangement as evidence of mixed NK/T-cell differentiation in a subset of sinonasal lymphomas.

Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia.

Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.

Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.

In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.

A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

ATM mutations and protein expression are not associated with familial B-CLL cases.

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.

Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.

The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.

Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity.

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.

Bovine serum albumin in the preparation of peripheral blood smears.

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Thalidomide for patients with recurrent lymphoma.

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

Myelodysplastic syndrome: from morphology to biology.

C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.

The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.

Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.

Mammalian target of rapamycin as a therapeutic target in leukemia.

Monoclonal antibodies in the treatment of leukemia.

Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

Thalidomide therapy for myelofibrosis with myeloid metaplasia.

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

Bi-clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status.

Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.

A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.

Higher detection rate of JAK2 mutation using plasma.

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

He use of the antibodies in the diagnosis of leukemia and lymphoma by flow cytometry.

Quantification of surface antigens and quantitative flow cytometry.

Monitoring cell signaling pathways by quantitative flow cytometry.

Cell-free bead-based detection of total and phosphorylated proteins in plasma and cell lysates: detection of FLT3.

Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab.

Detection of chromosome translocations by bead-based flow cytometry.

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.

Toward the identification of mesenchymal stem cells in bone marrow and peripheral blood for bone regeneration.

Liquid-based fluorescence in situ hybridization assay for detection of ERBB2 gene amplification in patients with breast cancer.

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

Plasma-based detection of clonality in lymphoid malignancies.

Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.

B-cell clones as early markers for chronic lymphocytic leukemia.

K-ras mutations and cetuximab in colorectal cancer.

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.

Proteomics-based prediction of clinical response in acute myeloid leukemia.

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics.

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.

Clinical correlation of circulating heat shock protein 70 in acute leukemia.

Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.

Circulating CD33 and its clinical value in acute leukemia.

Quantification of intracellular proteins and monitoring therapy using flow cytometry.

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Long-term follow-up of monoclonal B-cell lymphocytosis detected in environmental health studies.

Somatic mutations of signaling genes in non-small-cell lung cancer.

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

Circulating microRNAs as biomarkers for hepatocellular carcinoma.

MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.

Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.

Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.

Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens.

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.

Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.

The t(9;11) confers good prognosis in AML patients treated with stem cell transplantation as compared to non-t(9;11) and other adverse-risk abnormalities.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.

Dysregulation of ubiquitin-proteasome pathway and apolipoprotein A metabolism in sickle cell disease-related pulmonary arterial hypertension.

Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.

Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.

Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies.

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Prevalence and relative proportions of CLL and non-CLL monoclonal B-cell lymphocytosis phenotypes in the Middle Eastern population.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Emerging information on the use of rituximab in chronic lymphocytic leukemia.

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.